March 2023
Women's Health
Melissa McNeil, MD, MPH, MACP, Editor
The explosion of information about gender-specific conditions in the last two decades highlights the need for providers with an interest and knowledge about conditions unique to women (eg, menopause), more common in women (eg, osteoporosis), or which present differently in women (eg, cardiovascular disease). One has only to look at the changing views regarding hormone therapy (HT) to understand the need for up-to-date practitioners. In 1995, HT was thought to be beneficial for both primary and secondary cardiac prevention, to be effective in reducing osteoporotic fractures, and to pose no increased risk for breast cancer or thromboembolic events. Beginning with the early release of the Women’s Health Initiative results in 2001, these views have radically changed. We now would not use HT for either primary or secondary prevention of cardiac disease, and we appreciate increased risks of both breast cancer and thrombosis. The only “medical certainty” still standing is the belief that HT reduces osteoporotic fractures. However, the advent of new therapies, such as bisphosphonates and selective estrogen receptor modulators, has made even osteoporosis prevention a dubious indication for HT as a first-line treatment for osteoporosis.